NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Surv BioPharma Inc.

Surv BioPharma Inc.

Private
KagoshimaHealthcare & Life Scienceshttp://www.survbiopharma.co.jp/

Last Round

Series B

Extension

Dec 23, 2025

Total Funding Raised

$38.69M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Surv BioPharma Inc. is a biopharmaceutical company that develops oncolytic viruses and in vivo gene therapies for cancers and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

oncolytic virus therapycancer-killing virussurvivin promoterin vivo gene therapybone tumor treatmentdrug licensinggenetically modified virusbiotechrare cancer treatmentarmed oncolytic viruscancer immunotherapyadenovirus vectoruniversity spin-out

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Surv BioPharma Inc. Comps

Public and private peers based on sector, stage, and business model.

Surv BioPharma Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Surv BioPharma Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionDec 23, 2025
GrantDec 4, 2025
Series BNov 11, 2025
SeedDec 28, 2022

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 23, 2025

    $4.3M round with participation from TOHO HOLDINGS.

  • Dec 4, 2025

    $17.3M grant from Japan Agency for Medical Research and Development.

Surv BioPharma Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Surv BioPharma Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Surv BioPharma Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersKagoshima
Year Founded2022
Last FundingDec 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.